JP2023522250A5 - - Google Patents
Info
- Publication number
- JP2023522250A5 JP2023522250A5 JP2022564007A JP2022564007A JP2023522250A5 JP 2023522250 A5 JP2023522250 A5 JP 2023522250A5 JP 2022564007 A JP2022564007 A JP 2022564007A JP 2022564007 A JP2022564007 A JP 2022564007A JP 2023522250 A5 JP2023522250 A5 JP 2023522250A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- cancer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025062751A JP7906937B2 (ja) | 2020-04-24 | 2025-04-04 | 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20171280.9 | 2020-04-24 | ||
| EP20171280 | 2020-04-24 | ||
| PCT/EP2021/060167 WO2021214019A1 (en) | 2020-04-24 | 2021-04-20 | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025062751A Division JP7906937B2 (ja) | 2020-04-24 | 2025-04-04 | 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023522250A JP2023522250A (ja) | 2023-05-29 |
| JP2023522250A5 true JP2023522250A5 (cg-RX-API-DMAC7.html) | 2025-02-25 |
| JP7663603B2 JP7663603B2 (ja) | 2025-04-16 |
Family
ID=70464845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564009A Pending JP2023522251A (ja) | 2020-04-24 | 2021-04-20 | 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類 |
| JP2022564007A Active JP7663603B2 (ja) | 2020-04-24 | 2021-04-20 | 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564009A Pending JP2023522251A (ja) | 2020-04-24 | 2021-04-20 | 免疫活性化のためのdgkzeta阻害剤としての置換アミノチアゾール類 |
Country Status (32)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| AR120896A1 (es) | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| CA3180670A1 (en) | 2020-04-24 | 2021-10-28 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
| WO2022114164A1 (ja) | 2020-11-30 | 2022-06-02 | アステラス製薬株式会社 | ヘテロアリールカルボキシアミド化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117510497A (zh) * | 2022-07-29 | 2024-02-06 | 山东轩竹医药科技有限公司 | DGKζ抑制剂 |
| KR20250046309A (ko) * | 2022-08-08 | 2025-04-02 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 테트라졸릴 화합물 |
| TW202436351A (zh) | 2023-02-06 | 2024-09-16 | 德商拜耳廠股份有限公司 | Ccr8抗體及dgk抑制劑之組合 |
| CN120957975A (zh) | 2023-03-31 | 2025-11-14 | 拜耳公司 | (r)-2-(n-[4-氨基-5-(4-甲氧基苯甲酰基)噻唑-2-基]-4-氟-苯胺基)丙酰胺的微晶形式及其制备方法 |
| WO2024208198A1 (zh) * | 2023-04-06 | 2024-10-10 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的噻唑类化合物 |
| WO2024235203A1 (zh) * | 2023-05-15 | 2024-11-21 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的化合物 |
| WO2025061020A1 (zh) * | 2023-09-21 | 2025-03-27 | 楚浦创制(武汉)医药科技有限公司 | 苯并五元杂环衍生物及其制备方法与应用、药物组合物 |
| WO2025067360A1 (zh) * | 2023-09-27 | 2025-04-03 | 海思科医药集团股份有限公司 | 一种DGKzeta拮抗剂及其在医药上的应用 |
| CN121586707A (zh) * | 2023-10-17 | 2026-02-27 | 楚浦创制(武汉)医药科技有限公司 | 硫代羰基化合物及其应用 |
| WO2025082460A1 (zh) * | 2023-10-20 | 2025-04-24 | 上海先祥医药科技有限公司 | 二酰基甘油激酶抑制剂化合物及其应用 |
| WO2025167814A1 (zh) * | 2024-02-06 | 2025-08-14 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的化合物 |
| WO2026068294A1 (en) * | 2024-09-24 | 2026-04-02 | Bayer Aktiengesellschaft | Improved nanoseeding process |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001056567A1 (en) * | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
| US20040132124A1 (en) | 2002-03-22 | 2004-07-08 | Prescott Stephen M. | Neuroprotection by inhibition of diacyglycerol kinase epsilon activity |
| AU2003253364B2 (en) | 2002-08-07 | 2007-06-07 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
| US20050137239A1 (en) | 2003-12-17 | 2005-06-23 | Hines Michelle D. | Thiazole derivatives |
| NZ550114A (en) | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| JP2007533730A (ja) | 2004-04-20 | 2007-11-22 | アブ サイエンス | 筋炎および筋ジストロフィーを含む炎症性筋疾患を処置するためのc−kit阻害剤の使用法 |
| WO2005102318A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
| WO2005102326A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
| US20080004279A1 (en) | 2004-04-23 | 2008-01-03 | Alain Moussy | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases |
| EP1742633A2 (en) | 2004-04-23 | 2007-01-17 | AB Science | Use of c-kit inhibitors for treating fibrosis |
| JP2008503446A (ja) | 2004-05-06 | 2008-02-07 | プレキシコン,インコーポレーテッド | Pde4b阻害剤及びその使用 |
| US20070249628A1 (en) | 2004-05-18 | 2007-10-25 | Alain Moussy | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons |
| WO2005115385A1 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
| WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
| AU2006244203B2 (en) | 2005-05-09 | 2012-05-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| WO2007022415A2 (en) | 2005-08-18 | 2007-02-22 | Pharmacopeia, Inc. | Substituted 2-aminothiazoles for treating neurodegenerative diseases |
| GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| KR100903974B1 (ko) | 2007-09-27 | 2009-06-25 | 한국화학연구원 | 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 spc 수용체 활성으로 유발되는 염증관련 질환치료제 |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| CN102056483A (zh) | 2008-06-03 | 2011-05-11 | 西佳技术公司 | 用于治疗或预防登革病毒感染的小分子抑制剂 |
| JP5322296B2 (ja) | 2008-08-20 | 2013-10-23 | 日本曹達株式会社 | テトラゾイルオキシム誘導体を含む植物病害防除剤の使用方法 |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| WO2013033037A2 (en) | 2011-08-26 | 2013-03-07 | The Regents Of The University Of California | Novel antiprion compounds |
| CN103058949A (zh) | 2011-10-18 | 2013-04-24 | 华东理工大学 | 做为dhodh抑制剂的噻唑衍生物及其应用 |
| CN103159695B (zh) | 2011-12-08 | 2015-08-12 | 首都师范大学 | 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途 |
| GB201307233D0 (en) | 2013-04-22 | 2013-05-29 | Vib Vzw | Compounds and uses thereof |
| WO2014181287A1 (en) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| WO2015046193A1 (ja) | 2013-09-25 | 2015-04-02 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素環式アミン誘導体 |
| WO2015199206A1 (ja) | 2014-06-27 | 2015-12-30 | 塩野義製薬株式会社 | Trpv4阻害活性を有する6員環誘導体 |
| CN106109467B (zh) | 2016-06-20 | 2020-04-17 | 中国药科大学 | 三类羧基取代芳香化合物在耐吡嗪酰胺结核病及结核病治疗中的医药用途 |
| WO2018089902A1 (en) | 2016-11-13 | 2018-05-17 | Apogee Biotechnology Corporation | Diaminothiazole compounds, compositions and methods of use |
| WO2019133445A1 (en) * | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
| SG11202012973RA (en) * | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
| CN112654621B (zh) * | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| EP4013508A1 (en) * | 2019-08-12 | 2022-06-22 | Bayer Aktiengesellschaft | [1,2,4]triazolo[1,5-c]quinazolin-5-amines |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| JP2022547882A (ja) | 2019-09-06 | 2022-11-16 | インフレイゾーム リミテッド | Nlrp3阻害剤 |
| MX2022005376A (es) | 2019-11-04 | 2022-05-19 | Alector Llc | Moleculas de fusion del dominio extracelular (ecd) de la lectina 9 similar a inmunoglobulina que se une al acido sialico (siglec-9) y metodos de uso de las mismas. |
| AR120896A1 (es) | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| CN120737188A (zh) | 2020-04-24 | 2025-10-03 | 勃林格殷格翰国际有限公司 | 作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物 |
| CA3180670A1 (en) | 2020-04-24 | 2021-10-28 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
-
2021
- 2021-04-20 CA CA3180670A patent/CA3180670A1/en active Pending
- 2021-04-20 CR CR20220536A patent/CR20220536A/es unknown
- 2021-04-20 MA MA59379A patent/MA59379B1/fr unknown
- 2021-04-20 US US17/920,679 patent/US12673927B2/en active Active
- 2021-04-20 PL PL21720249.8T patent/PL4139286T3/pl unknown
- 2021-04-20 SI SI202130304T patent/SI4139286T1/sl unknown
- 2021-04-20 CN CN202510268418.9A patent/CN120093741A/zh active Pending
- 2021-04-20 CN CN202510268420.6A patent/CN120093742A/zh active Pending
- 2021-04-20 CN CN202510268417.4A patent/CN120093740A/zh active Pending
- 2021-04-20 IL IL297499A patent/IL297499A/en unknown
- 2021-04-20 WO PCT/EP2021/060167 patent/WO2021214019A1/en not_active Ceased
- 2021-04-20 HR HRP20250519TT patent/HRP20250519T1/hr unknown
- 2021-04-20 JP JP2022564009A patent/JP2023522251A/ja active Pending
- 2021-04-20 JP JP2022564007A patent/JP7663603B2/ja active Active
- 2021-04-20 EP EP21720249.8A patent/EP4139286B1/en active Active
- 2021-04-20 CN CN202510268414.0A patent/CN120093739A/zh active Pending
- 2021-04-20 PT PT217202498T patent/PT4139286T/pt unknown
- 2021-04-20 CN CN202180037365.XA patent/CN115697979B/zh active Active
- 2021-04-20 FI FIEP21720249.8T patent/FI4139286T3/fi active
- 2021-04-20 EP EP21720251.4A patent/EP4139287B1/en active Active
- 2021-04-20 KR KR1020227040664A patent/KR20230005247A/ko not_active Withdrawn
- 2021-04-20 PE PE2022002433A patent/PE20230322A1/es unknown
- 2021-04-20 DK DK21720249.8T patent/DK4139286T3/da active
- 2021-04-20 CA CA3180819A patent/CA3180819A1/en active Pending
- 2021-04-20 AU AU2021261524A patent/AU2021261524A1/en active Pending
- 2021-04-20 MX MX2022013388A patent/MX2022013388A/es unknown
- 2021-04-20 CN CN202180043311.4A patent/CN115697980B/zh active Active
- 2021-04-20 ES ES21720249T patent/ES3029140T3/es active Active
- 2021-04-20 GE GEAP202116095A patent/GEP20257731B/en unknown
- 2021-04-20 RS RS20250474A patent/RS66889B1/sr unknown
- 2021-04-20 PH PH1/2022/552828A patent/PH12022552828A1/en unknown
- 2021-04-20 US US17/921,043 patent/US20230167103A1/en not_active Abandoned
- 2021-04-20 LT LTEPPCT/EP2021/060167T patent/LT4139286T/lt unknown
- 2021-04-20 HU HUE21720249A patent/HUE071024T2/hu unknown
- 2021-04-20 GE GEAP202416095A patent/GEAP202416095A/en unknown
- 2021-04-20 WO PCT/EP2021/060170 patent/WO2021214020A1/en not_active Ceased
- 2021-04-23 AR ARP210101100A patent/AR121929A1/es unknown
- 2021-04-23 TW TW110114675A patent/TWI894261B/zh active
-
2022
- 2022-09-14 US US17/944,922 patent/US11964953B2/en active Active
- 2022-10-17 EC ECSENADI202280829A patent/ECSP22080829A/es unknown
- 2022-10-17 DO DO2022000223A patent/DOP2022000223A/es unknown
- 2022-10-19 CO CONC2022/0014876A patent/CO2022014876A2/es unknown
- 2022-10-21 CL CL2022002919A patent/CL2022002919A1/es unknown
- 2022-10-24 JO JOJO/P/2022/0267A patent/JOP20220267A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023504249A5 (cg-RX-API-DMAC7.html) | ||
| JP2023506532A5 (cg-RX-API-DMAC7.html) | ||
| JP2021526132A5 (cg-RX-API-DMAC7.html) | ||
| JP2021521194A5 (cg-RX-API-DMAC7.html) | ||
| JP2022532790A5 (cg-RX-API-DMAC7.html) | ||
| JP2022121594A5 (cg-RX-API-DMAC7.html) | ||
| US9192645B2 (en) | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof | |
| US8435959B2 (en) | Effective treatment of tumors and cancer with triciribine and related compounds | |
| KR20220050143A (ko) | Kras-관련 암 치료 방법 | |
| JP2019535749A5 (cg-RX-API-DMAC7.html) | ||
| JP2019519498A5 (cg-RX-API-DMAC7.html) | ||
| JP2021525768A5 (cg-RX-API-DMAC7.html) | ||
| JP2016528162A5 (cg-RX-API-DMAC7.html) | ||
| WO2008086005A1 (en) | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof | |
| JP2014097929A5 (cg-RX-API-DMAC7.html) | ||
| JP6620338B2 (ja) | 低用量ナルトレキソンによるがん細胞の準備刺激 | |
| CN114867622A (zh) | 涉及二芳基巨环化合物的组合疗法 | |
| JP2018515618A (ja) | がん治療 | |
| US9486522B2 (en) | Compositions including triciribine and trastuzumab and methods of use thereof | |
| RU2019142694A (ru) | Композиции и способы, которые можно использовать для лечения пролиферативных заболеваний | |
| TW201938543A (zh) | 三取代之苯并三唑衍生物的使用方法 | |
| KR20170045237A (ko) | 항-pd1 또는 항-pdl1 단클론성 항체와 조합된 시티딘 유사체의 경구 제제를 사용한 질환 또는 장애를 치료하는 방법 | |
| CN117956998A (zh) | 治疗kras突变的癌症患者 | |
| JP2013528215A5 (cg-RX-API-DMAC7.html) | ||
| JP2023500857A (ja) | 新規な化合物およびそれを含むがんの予防または治療用薬学組成物 |